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The development of chimeric antigen receptor (CAR) T cell therapy has introduced a new
and effective strategy to guide and promote the immune response against tumors in the
clinic. More recently, in an attempt to enhance its utility, this method has been expanded
to novel cell types. One of the more successful variants has proven to be the expression of
CARs in Natural Killer (NK) cells (CAR-NK). Gene engineering NK cells to express an
exogenous CAR receptor allows the innate anti-tumor ability of NK cells to be harnessed
and directed against a target tumor antigen. In addition, the biology of NK cells allows the
development of an allogeneic cell therapeutic product useable with most or all patient
haplotypes. NK cells cause little or no graft versus host disease (GvHD) and are therefore
suitable for development of an “off the shelf” therapeutic product. Initial trials have also
shown that CAR-NK cells rarely cause cytokine release syndrome. However, despite their
potential NK cells have proven to be difficult to engineer, with high sensitivity to apoptosis
and low levels of gene expression. The creation of optimized methods to introduce genes
into NK cells will promote the widespread application of CAR-NK in research laboratories
and the clinics.
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NK cells are a subpopulation of lymphocytes central to the innate immune system and the innate
response to viruses. In peripheral blood, ~10% of mononuclear cells are NK cells and are thus readily
isolated from density gradient preparations of peripheral blood mononuclear cells (PBMC). NK cells
are intrinsically unreactive to foreignmajor histocompatibility (MHC)molecules. This hasmade them
an attractive alternative for generation of therapeutic cell products, as their insensitivity to antigens
presented byMHCallows them tobe used in an allogenic contextwithminimal risk of graft versus host
disease (GvHD). Although NK cells carry activating and inhibitory receptors forMHCmolecules, the
MHCmismatch between graft and host is usually not sufficient to contribute to pathology (1). Recent
research indicates, however, that host-specific factorsmay be important to optimize their potential (2).
Furthermore, improvements increasinghoming to sites of tumor growth such as bonemarrowor to the
tumor itself by enhanced chemokine receptors have shown promise (3, 4).
Chimeric antigen receptors (CARs) are receptorproteins that have been engineered to allow specific
recognition of a target protein and induction of secondary signaling. The recognition domain is usually
derived from the antigen-binding regions of an antibody. This is presented on the cell surface by aorg January 2021 | Volume 11 | Article 6111631
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bound by a transmembrane domain to intracellular signaling
domains, usually CD3-zeta. Costimulatory domains are also
often included intracellularly to enhance signaling and longevity
post activation. CARs have mostly been used in T cells to retarget
them against tumors. The CAR uses the existing T cell cytotoxic
machinery to destroy the targeted malignant cells. The fact that
other cell types are also known to attack tumor cells prompted
recent interest inCAR expression in non–T cells. Themost notable
success has been the Natural Killer (NK) cell. NK cells were first
identified by their unique ability to kill tumor cells without prior
antigen priming. NK cells with CAR receptors (CAR-NK) have
nowbeen recognized as a potent tool against cancer (5–8). Initially,
the creation of CAR-NK cells was undertaken with constructs
developed for CAR-T cells; however, recent developments have
incorporated adaptions to NK cells. Nevertheless, NK cells pose
special anduniqueproblems.UnlikeT cells andB cells,NKcells are
not typically clonally expanded, making the generation,
maintenance and expansion of CAR-NK cells challenging. The
most important stage in the generation of NK-CAR cells is the
introduction of the genetic element into the NK cell itself
(Figure 1) and the subsequent expansion of the CAR-NK cells.Frontiers in Immunology | www.frontiersin.org 2SOURCES OF NATURAL KILLER CELLS
Peripheral-blood derived NK cells can be readily isolated from
peripheral blood but are difficult to engineer. The reasons behind
this are unclear but include low transduction efficiency combined
with poor expansion. In order to avoid this bottleneck NK cells
have been generated from induced pluripotent stem cells (iPSC),
which can yield many more cells and are more permissive to
engineering (9). NK cells can also be generated from umbilical
cord blood. NK cells from this source are more readily
engineered due to their higher proliferative capacity, as was
recently demonstrated in the first published clinical trial
of CAR-NK cells (10). Despite this success, a possible
disadvantage is the relatively immature nature of cord blood
derived NK cells. Several trials have used NK cell lines,
particularly cell line NK-92 (8). Cell lines are relatively easy to
engineer but are undesirable both due to safety considerations
and as they must be lethally irradiated before administration, so
they cannot persist in the host and cannot therefore give long-
term protection. Recently, feeder cell lines have come into
common use to expand NK cells ex vivo. These MHC-negative
cells lines, in particular K562, are often engineered to expressFIGURE 1 | Comparison of methods for genetic engineering of NK cells. Viral transduction (pink, upper) and non-viral electroporation (green, lower) methods of
gene engineering NK cells are illustrated with advantages and disadvantages noted.January 2021 | Volume 11 | Article 611163
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before being used (11).NON-VIRAL CAR-NATURAL KILLER CELL
ENGINEERING: mRNA AND DNA
TRANSFECTION
In contrast to gene expression via viral vectors CAR expression
with non-viral–based methods is usually transient, being
present for a few days (12). Although long-term expression
can be achieved if the sequence can integrate, as is the case
with transposon-based systems (13). Typically, nucleic acid
introduction is achieved by electroporation, which is a simple
and cost-effective method and therefore appropriate for large-
scale clinical applications. A major disadvantage is that the
permeabilization of the cell membrane by electric pulses can
easily result in high cell death rates by unregulated exchange of
interior or exterior cell components or the creation of permanent
membrane leakage (14).mRNA TRANSFECTION OF NATURAL
KILLER CELLS
Primary CAR-NK generation by mRNA electroporation was
initially investigated in 2010 by using an anti-CD19 transgene
for transfection in unstimulated and expanded NK cells (15).
Expression of the CAR ranged from 33% to 81%. It has been
determined that for clinical products expression of a CAR after
electroporation is dependent on the dose of mRNA (25–200 µg/
ml) and increases the more nucleic acid is applied (16).
Interestingly, the viability of expanded cells after one day post-
transfection was lower (54%) than for unexpanded cells (64%)
(15). However, other groups were not able to transfect peripheral
blood or cord blood derived NK cells at transfection rates higher
than 10% even with IL-2 stimulation (17). In contrast
transfection efficiency for the NK-92 cell line with mRNA
encoding an anti-CD19 CAR resulted in higher yields (47.2 ±
8%) (18). More recent protocols have achieved efficient
expression of a duration of at least 72 h (3, 19). Recently it has
been shown that the co-expression of two transgenes, one being a
CAR and the other a chemokine receptor is possible using
mRNA electroporation. This yields a transfection rate of 90%
modified cells (3). Typically, 5 µg of capped, polyadenylated
mRNA is electroporated in a 2-mm cuvette using a voltage of
240–500 V for 4–5 ms (3, 19).
The transfer ofmRNAtransfection into the clinichas beenaided
bya recently publishedprotocol for large-scaleNKcell expansion in
compliance with current Good Manufacturing Practice (cGMP)
(20). Large-scale cGMP-compliant electroporation systems such as
MaxCyte or CliniMacs are now available for the generation of
therapeutic product.
The introduction of CAR mRNA into resting NK cells using a
chemical method (charge-altering releasable transporters, orFrontiers in Immunology | www.frontiersin.org 3CARTs) has been recently reported (21). This method
combined both a higher efficiency compared to electroporation
using the 4D nucleofector device and caused less damage and
phenotypic change. Finally, CAR-NK cells derived were
cytotoxic to CD19+ target cells.
In summary, mRNA transfection is highly efficient but with
significant drawbacks. Transfection of complex multigene
constructs often necessitates cotransfection of separate mRNA
due in part to the difficulty in generating long mRNA sequences.
Furthermore, despite its efficiency mRNA is inherently labile,
being non-integrative and non-replicative, resulting in a very
short period of expression.DNA TRANSFECTION OF NATURAL
KILLER CELLS
Initially, electroporation with DNA was reported successfully for
the cell line NK-92 (18) but not for freshly isolated or expanded
human NK cells. In a recently published protocol, however, the
authors were able to transfect IL-2 expanded primary NK cells by
prior optimization of plasmid DNA concentration, target cell
number, plasmid size, buffer conditions, voltage, and number
and width of pulses (22). Each optimization step contributed to
efficiency of transfection with no single element dominating. In
contrast, for resting NK cells cell number was of paramount
importance with 2–6 × 107 cells/ml being the optimal range.
After using the new protocol to transfect a first- and second-
generation CAR into IL-2 expanded NK cells, 40% transfected
cells were observed with a cell viability to up ~60%. This
represents a 5-fold increase in efficiency over standard
protocols (22). After DNA electroporation the viability of cells
is lower compared to mRNA electroporation, probably due to the
harsher transfection conditions needed for DNA to reach the NK
cell nucleus (18) or due to activation of the innate immune
system. Transfected DNA is more durable than mRNA, with
expression persisting up to 15 days (23).
To summarize, DNA transfection is less efficient, however
complex constructs can be readily introduced and like mRNA
non-integrated DNA is self-limiting which thus gives a favorable
safety profile compared to viral methods (22).TRANSDUCTION OF NATURAL KILLER
CELLS: VIRAL VECTORS
Transduction refers to the introduction of genetic material via
viral vectors, including the retroviral and lentiviral-based vectors
(24). During the life-cycle of retroviruses viral RNA is reverse
transcribed into double-stranded cDNA which is then semi-
randomly integrated into the genome of the infected cell (25).
For these reasons, this strategy typically takes longer until the
gene is expressed. Vectors based on these pathogens have several
advantages making it relatively simple to create complex vectors
and subsequently reliably introduce them into cells. Typically,
these vectors can be up to 10 kb in size without incurring significantJanuary 2021 | Volume 11 | Article 611163
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Furthermore, as these vectors integrate, this allows the permanent
modification of the cell in the absence of antibiotic resistance
markers. The modified cells can then be maintained in the host
over long periods of time.
The sensitivity of NK cells to foreign genetic material and the
stressful process of transduction typically results in low levels of
transduction and high apoptosis. Efficiency in transfecting NK
cells is therefore relatively low compared to T-cells. This is due to
resistance to viral transduction from innate defense mechanisms
guided by pattern recognition receptors recognizing foreign
genetic material (26, 27). In order to prevent this inhibitory
chemicals such as BX795, which inhibits PDK1, can be added
during transduction. This blocks activation of signaling pathways
mediated by RIG-I like receptors or Toll-like receptor 3 (28). It
has been demonstrated that lentiviral transduction efficiency can
be enhanced ~4 fold by this strategy (29). Nevertheless, it is
sometimes necessary to use multiple rounds of transduction to
achieve an adequate transgene expression (30).
In order to increase the safety profile of viral vectors, expression
systems have been created where the envelope protein is expressed
on a separate plasmid. This allows safe generation ofmodified viral
particles with exogenous envelope proteins, in a process termed
pseudotyping. One way of enhancing transduction of NK cells is
the selection of the best pseudotyping envelope protein. The
commonly used vesicular stomatitis virus (VSV) glycoprotein G
is usually highly efficient, as it binds to the LDL receptor which is
present in a wide variety of cells (31). However, it is inefficient for
infection of lymphoid cells, requiring high viral titers which in turn
are often toxic to the cells. The choice of envelope proteins from
lymphotropic viruses such as measles or baboon retrovirus,
however, has been shown to improve both transduction and
integration (32). Successful transduction also depends on
diffusion of the virus to the cell surface and adsorption into the
target. Enveloped viral particles are typically negatively charged as
they derive from the cell membrane. This results in repulsion of
virion and cell, interfering with transduction. Cationic polymers
such as hexadimethrine bromide (polybrene) or protamine sulfate
are used to neutralize the negative charge of the virion, allowing
better adsorption efficiency and membrane fusion (33). An
alternative strategy is to enhance colocalization of cells and virus
by using crosslinking agents such as Retronectin or Vectofusin-1.
These have been reported to outperform their cationic polymer
counterparts (17, 34). Retronectin, a chimeric peptide derived from
fibronectin, promotes the interaction and colocalization between
virus particles and counterparts on the cell surface (34). Similarly,
Vectofusin-1 facilitates the adhesionand the fusionof the viruswith
the cellular plasma membrane, although the concrete mechanism
remains unclear (35). There is no consensus on which enhancer
shows greater optimization of transduction (35, 36).RETROVIRAL VECTORS
Vectors generated from the related alpharetroviral and
gammaretroviral viruses have been used to transduce primaryFrontiers in Immunology | www.frontiersin.org 4lymphatic cells, including NK cells (30, 37). A significant
limitation for retroviral transduction is that retroviral cDNA
can only integrate into the NK cell genome during mitosis when
the nuclear membrane dissolves. This requirement is particularly
problematic in non-replicating primary cells, but less so for
activated NK cell lines (38).LENTIVIRAL VECTORS
Lentiviral vectors are considered genetically more complex and in
contrast to their retroviral counterparts can integrate their genetic
information into non-dividing cells (39). Recent data shows that
the performance of lentiviral vectors in generating CAR-NK cells
depends on the envelope protein they express. For the commonly
used VSV-G envelope proteins the highest transduction efficiency
of primary NK cells using VSV-G pseudotyped particles was
found with lentiviral vectors compared to retroviral vectors (34).
Which envelope protein has the best performance is unclear as the
transduction efficiency for lentiviral vectors pseudotyped with
VSV-G or feline endogenous retrovirus envelope protein
RD114-TR was similar for primary human NK cells (34).
Another group found that a lentiviral/VSV-G vector produced
less CD19-CAR expressing cells compared to a RD114-TR
pseudotyped lentiviral vector (36). Furthermore, a Baboon
envelope pseudotyped lentiviral vector BaEV-LV was
significantly better than both the RD-114-TR as well as VSV-G
pseudotyped lentiviral vector (32). VSG-V binds to the low density
lipid receptor LDL-R which is poorly expressed on activated NK
cells (5). In contrast, RD114 binds to the sodium-dependent
neutral amino acid transporter ASCT-1 and ASCT-2, as does
the BaEV envelope protein (40–42). The ASCT-1 transporter is
strongly expressed on NK cells and ASCT-2 is upregulated after
activation of NK cells with IL-2 and IL-15 (5). The BaEV envelope
protein has also been shown to bind to the glycosylated form of
ASCT-1 in contrast to RD-114-TR. This may explain its greater
efficiency in transduction (42).
It has been reported that lentiviral transduction can be further
optimized by using spinfection, a method where centrifugation at
a low RPM is applied. Spinfection transduction rates range from
19% to 73% with CD19 CAR lentiviral transduced cord blood
derived NK cells, compared to a range from 12% to 30% for static
transduction (17).
In terms of optimization for transduction protocols Müller et al.
compared alpharetroviral vectors with lentiviral vectors. A RD114-
TR pseudotyped alpharetroviral vector could achieve 82.9% of NKs
transduced with CD19 CAR using Vectofusin-1–based
transduction (36). A similar comparative study of viral vectors
from Suerth et al. confirms the superiority in transfection efficiency
when a RD114-TR pseudotyped alpharetroviral vector was used.
Although transduction was performed with Rectofusin both
transduction enhancers reliably optimized transduction efficiency
(34). It is thought that Vectofusin-1 might be beneficial for large-
scale expansion due to a simpler usage (36). Because of the stable
high rate of transgene expression by using a RD114-TR
alpharetroviral vector Kellner et al. established a protocol forJanuary 2021 | Volume 11 | Article 611163
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Following the instructions, transduction procedure resulted in
>90% CAR transduced cells (43). In order to achieve this
efficiency proliferating NK cells were transduced using
retronectin. A possible drawback of this method, however, is the
use of the K-562 cell line to expand the NK cells both prior and post
transduction. Furthermore, a relatively simple CAR was used to
transduce (43). In conclusion, there is no currently available gene
transfer method that is universally applicable. All have advantages
and drawbacks which we have illustrated in Figure 1.OUTLOOK
Several novel methods to introduce genes into NK cells are under
development. These include alternative viral vectors with a
higher safety profile such as adenovirus associated virus (AAV)
vectors. Advances in mRNA generation and electroporation
technology will also bring improved transfection. Combining
the two methods, for example with transposons or with CRISPR/
Cas9-based integration, would combine long term expression
with the efficiency of electroporation. Transposon technology in
particular offers integration without complex, expensive, and
potentially dangerous viral transduction systems. One
disadvantage that remains with this system is its relative
inefficiency. Finally, improvement in primary NK expansion
protocols will also bring an improvement in gene engineering,
as healthy proliferating cells are more readily engineered. The
vectors themselves will also be become optimized to the NK
microenvironment, for example by using DAP12 or NKG2D
signaling domains. Which construct is best suited for NK cells is
a focus of current research.
The durability of the CAR-NK cells within the host is also
currently a matter of debate. CAR-T cells can persist in the host
for years and there is clear data showing that this contributes to
tumor clearance. Whether this is the case for CAR-NK cells isFrontiers in Immunology | www.frontiersin.org 5unclear. It is currently accepted that allogenic NK cells have a
relatively short half-life (44), although persistence of CAR-NK
cells in vivo for at least 1 year has been recently reported (10).
Long-term follow up of clinical trials of primary NK cells will
elucidate if persistence of CAR-NK cells contributes to
therapeutic efficacy.CONCLUDING REMARKS
Although NK cells have many desirable characteristics, there
remain significant problems in the production of CAR-NK cells
for therapeutic purposes. The introduction of foreign genetic
material and subsequent expansion of the NK cells is difficult,
making the development of feasible and reproducible GMP
protocols a challenge. The viability of the CAR-NK cells is
central to the success of the therapeutic product, as the long-
term persistence of tumor-specific CAR cells in the host is
thought to promote the therapeutic efficacy.
Currently, the most successful alternatives for introducing
genes into NK cells are either rapid transient expression by
electroporation or slow sustained expression by viral vectors. The
correct choice of transfection protocol is thus an important
element in the design and execution of a successful clinical trial.AUTHOR CONTRIBUTIONS
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